Top

Cost Effectiveness and Resource Allocation

Published in:

Open Access 01-12-2006 | Research

Resource use among patients with diabetes, diabetic neuropathy, or diabetes with depression

Authors: Trong K Le, Stephen L Able, Maureen J Lage

Published in: Cost Effectiveness and Resource Allocation | Issue 1/2006

Abstract

Background

Diabetes is often associated with complications and comorbidities. The purpose of this research is to compare medical resources used by patients with the following diagnoses: diabetes mellitus (DM), diabetic neuropathy (DN), and diabetes mellitus combined with comorbid depression (DD).

Methods

Adult patients who were diagnosed with DM, DN, or DD were included in the study. There were 55,972 patients in the DM cohort, 2,146 in the DN, and 2,379 in the DD. P values for comparisons between the three mutually exclusive cohorts were conducted using the Tukey-Kramer method. Cost comparisons among the cohorts were conducted using a stepwise multivariate regression that controlled for patient characteristics and comorbid conditions.

Results

Individuals in the DM or DN cohorts were generally more likely to use antidiabetic medications than patients in the DD group. Those diagnosed with DN or DD generally used more pain medications than individuals in the DM cohort. The DM cohort had significantly lower diabetes-related total medical costs ($1,297 v $5,125, p < 0.0001) and lower total medical costs ($4,819 v $24,765, p < 0.0001) than the DN cohort. The DM cohort also had significantly lower diabetes-related total medical costs ($1,297 v $3,264, p < 0.0001) as well as significantly lower total medical costs ($4,819 v $19,298, p < 0.0001) than the DD cohort.

Conclusion

Results from this study indicated significant differences in demographic characteristics, comorbidities, and medication use among individuals diagnosed with DM, DN, or DD. These differences translated into significant cost differences. Patients diagnosed with DN or DD had higher diabetes-related costs than patients diagnosed with DM.

Centers for Disease Control and Prevention: National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2003. Rev ed. Atlanta, GA: U.S. Department of Health and Human Services, Center for Disease Control and Prevention; 2004. [http://www.cdc.gov/diabetes/pubs/estimates.htm]

American Diabetes Association and the National Pharmaceutical Council. A closer look at diabetes [http://www.npcnow.org/resources/disease/diabetes.asp]

American Diabetes Association: Economic consequences of diabetes mellitus in the U.S. in 1997. Diabetes Care 1998, 21: 296–309.CrossRef

American Diabetes Association [http://www.diabetes.org/diabetes-statistics.jsp]

U.S. Bureau of the Census: Population Projections [http://www.census.gov/population/www/projections/popproj.html]

American Diabetes Association: Economic costs of diabetes in the U.S. in 2002. Diabetes Care 2003, 26: 917–932.CrossRef

Morgan CL, Currie CJ, Stott NC, et al.: The prevalence of multiple diabetes-related complications. Diabetic Medicine 2003,17(2):146–151. 10.1046/j.1464-5491.2000.00222.xCrossRef

Vinik AI, Park TS, Stansberry KB, Pittenger GL: Diabetic neuropathies. Diabetologia 2003, 43: 957–973. 10.1007/s001250051477CrossRef

Coffey JT, Brandle M, Zhou H, et al.: Valuing health-related quality of life in diabetes. Diabetes Care 2002, 25: 2238–2243.PubMedCrossRef

10.

Dyck PJ, Kratz KM, Karnes JL, et al.: The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester diabetic neuropathy study. Neurology 1993, 43: 817–824.PubMedCrossRef

11.

Feldman EL, Russell JW, Sullivan KA, Golovoy D: New insights into the pathogenesis of diabetic neuropathy. Curr Opin Neurol 1999,12(5):553–563. 10.1097/00019052-199910000-00009PubMedCrossRef

12.

Tesfaye S, Stevens LK, Stephenson JM, the EURODIAB IDDM Study Group, et al.: Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM Complications Study. Diabetologia 1996, 39: 1377–1384. 10.1007/s001250050586PubMedCrossRef

13.

Anderson RJ, Freedland KE, Clouse RE, Lustman PJ: The prevalence of comorbid depression in adults with diabetes: A meta-analysis. Diabetes Care 2001, 24: 1069–1078.PubMedCrossRef

14.

Lustman PJ: Anxiety disorders in adults with diabetes mellitus. Psychiatr Clin North Am 1998,11(2):419–432.

15.

Nichols GA, Brown JB: Unadjusted and adjusted prevalence of diagnosed depression in type 2 diabetes. Diabetes Care 2003,26(3):744–749.PubMedCrossRef

16.

Finkelstein EA, Bray JW, Chen H, et al.: Prevalence and costs of major depression among elderly claimants with diabetes. Diabetes Care 2003,26(2):415–420.PubMedCrossRef

17.

Ciechanowski PS, Katon WJ, Russo JE: Depression and diabetes: impact of depressive symptoms on adherence, function, and costs. Arch Intern Med 2000, 160: 3278–3285. 10.1001/archinte.160.21.3278PubMedCrossRef

18.

Gary TL, Crum RM, Cooper-Patrick L, Ford D, Brancati FL: Depressive symptoms and metabolic control in African-Americans with type 2 diabetes. Diabetes Care 2000, 23: 23–29.PubMedCrossRef

19.

Hanninen JA, Takala JK, Keinanen-Kiukaanniemi SM: Depression in subjects with type 2 diabetes: predictive factors and relation to quality of life. Diabetes Care 1999, 22: 997–998.PubMedCrossRef

20.

Goodnick PJ: Use of antidepressants in treatment of comorbid diabetes mellitus and depression as well as in diabetic neuropathy. Ann Clin Psychiatr 2001,3(1):31–41. 10.1023/A:1009012815127CrossRef

21.

SAS User's Guide: SAS/STAT User's Guide: Version 8. NC: SAS Institute; 1999.

22.

Takkinen S, Gold C, Pedersen NL, Malmberg B, Nilsson S, Rovine M: Gender differences in depression: A study of older unlike-sex twins. Aging Ment Health 2004,8(3):187–195. 10.1080/13607860410001669714PubMedCrossRef

23.

Parker G, Hadzi-Pavlovic D: Is the female preponderance in major depression secondary to a gender difference in specific anxiety disorders? Psychol Med 2004,34(3):461–470. 10.1017/S0033291703001181PubMedCrossRef

24.

Johnson JA, Majunder SR, Simpson SH, Toth EL: Decreased mortality associated with the use of metformin compared to sulfonylurea monotherapy in type 2 diabetes. Diabetes Care 2002, 25: 2244–2248.PubMedCrossRef

25.

United Kingdom Prospective Diabetes Study (UKPDS Group): Effect of intensive blood-glucose control with metformin or complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998, 352: 854–858. 10.1016/S0140-6736(98)07037-8CrossRef

26.

United Kingdom Prospective Diabetes Study (UKPDS Group): A randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes (UKPDS 28). Diabetes Care 1998, 21: 87–92.CrossRef

27.

Inzucchi SE: Oral anti hyperglycemic therapy for type 2 diabetes: scientific review. JAMA 2002, 287: 360–372. 10.1001/jama.287.3.360PubMedCrossRef

28.

Holmboe ES: Oral anti hyperglycemic therapy for type 2 diabetes: clinical applications. JAMA 2002, 287: 373–376. 10.1001/jama.287.3.373PubMedCrossRef

29.

Weinstock RS, Hawley G, Repke D, Feserstein BL, Sawin CT, Pogach LA: Pharmacy costs and glycemic control in the department of veteran affairs. Diabetes Care 2004,27(Suppl 2):674–681.

30.

Poncelet AN: Diabetic polyneuropathy: risk factors, patterns of presentation, diagnosis, and treatment. Geriatrics 2003,58(6):16–30.PubMed

31.

Agid O, Lerer B: Algorithm-based treatment of major depression in an outpatient clinic: clinical correlates of response to a specific serotonin reuptake inhibitor and to triodothyronine augmentation. Int J Neuropsychopharmacol 2003,6(1):41–49. 10.1017/S146114570200322XPubMedCrossRef

32.

Dobrez DG, Melfi CA, Croghan TW, Kenisner JJ, Obenchain RI: Antidepressant treatment for depression: total charges and therapy duration. J Ment Health Policy Econ 2000,3(4):187–197. 10.1002/mhp.95PubMedCrossRef

33.

Revicki F, Sorenson SV, Shih YC: The economics of selective serotonin reuptake inhibitors in depression: a critical review. CNS Drugs 2001,15(1):59–83. 10.2165/00023210-200115010-00005PubMedCrossRef

34.

Egede LE, Zheng D, Simpson K: Comorbid depression is associated with increased health care use and expenditures in individuals with diabetes. Diabetes Care 2002, 25: 464–470.PubMedCrossRef

35.

Lin EH, Katon W, Von Korff M, Rutter C, Simon GE, Oliver M, Cichanowski P, Ludman EJ, Bush T, Young B: Relationship of depression and diabetes self-care, medication adherence, and preventive care. Diabetes Care 2004,27(9):2154–2160.PubMedCrossRef

36.

Berger A, Dukes EM, Oster G: Clinical characteristics and economic costs of patients with painful neuropathic disorders. J Pain 2004,5(3):143–149. 10.1016/j.jpain.2003.12.004PubMedCrossRef

37.

Lin T, Chou P, Tsai ST, Lee YC, Tai TY: Predicting factors associated with costs of diabetic patients in Taiwan. Diabetes Res Clin Pract 2004,63(2):119–125. 10.1016/j.diabres.2003.09.006PubMedCrossRef

38.

Williams R, Van Gaal L, Lucioni C, CODE-2 Advisory Board: Assessing the impact of complications on the costs of Type II diabetes. Diabetologia 2002,45(7):S13-S17.PubMedCrossRef

39.

Gordois A, Scuffham P, Shaerer A, Oglesby A, Tobian JA: The health care costs of diabetic peripheral neuropathy in the US. Diabetes Care 2003,26(6):1790–1795.PubMedCrossRef

40.

Killilea T: Long-term consequences of type 2 diabetes mellitus: economic impact on society and managed care. Am J Manag Care 2002,8(16 Suppl):S441-S449.PubMed

41.

Hogan P, Dall T, Nikolov P: American Diabetes Association. Economic costs of diabetes in the US in 2002. Diabetes Care 2003,26(3):917–932.PubMedCrossRef

42.

Ramsey S, Summers KH, Leong SA, Birnbaum HG, Kemner JE, Greenberg P: Productivity and medical costs of diabetes in a large employer population. Diabetes Care 2002,25(1):23–29.PubMedCrossRef

43.

Hodgson TA, Cohen AJ: Medical care expenditures for diabetes, its chronic complications, and its comorbidities. Prev med 1999,29(3):173–186. 10.1006/pmed.1999.0534PubMedCrossRef

44.

Kalsekar ID, Madhaven SM, Amonkar MM, Scott V, Douglas SM, Makela E: The effect of depression on health care utilization and costs in patients with type 2 diabetes. Manag Care Interface 2006,19(3):39–46.PubMed

45.

Simon GE, Katon WJ, Lin EH, Ludman E, VonKorff M, Ciechanowski P, Young BA: Diabetes complications and depression as predictors of health services costs. Gen Hosp Psychiatry 2005,27(5):344–351. 10.1016/j.genhosppsych.2005.04.008PubMedCrossRef

46.

Caro JJ, Ward AJ, O'Brien JA: Lifetime costs of complications resulting from type 2 diabetes in the U.S. Diabetes Care 2002,25(3):476–81.PubMedCrossRef

Title: Resource use among patients with diabetes, diabetic neuropathy, or diabetes with depression
Authors: Trong K Le
Stephen L Able
Maureen J Lage
Publication date: 01-12-2006
Publisher: BioMed Central
Published in: Cost Effectiveness and Resource Allocation / Issue 1/2006
Electronic ISSN: 1478-7547
DOI: https://doi.org/10.1186/1478-7547-4-18

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Resource use among patients with diabetes, diabetic neuropathy, or diabetes with depression

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2006

Economic evaluation of a clinical protocol for diagnosing emergency patients with suspected pulmonary embolism

Accounting for the increase in NSAID expenditure: substitution or leakage?

Using cost-effectiveness analyses to inform policy: the case of antiretroviral therapy in Thailand

Economics of immunization information systems in the United States: assessing costs and efficiency

Priority setting of health interventions: the need for multi-criteria decision analysis

Enhancing the comparability of costing methods: cross-country variability in the prices of non-traded inputs to health programmes